ArticleInfection and immunity2006
Chronic Salmonella enterica serovar Typhimurium-induced colitis and cholangitis in streptomycin-pretreated Nramp1+/+ mice.
Article in Infection and immunity, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 79 citations in OpenAlex.
- Article
- Vaccine-enhanced competition permits rational bacterial strain replacement in the gut.Science (New York, N.Y.) · 2025Article
- Differential antibiosis predisposes mice to Campylobacter jejuni infection: Deeper insights into the impact of the gut microbiota composition in colonization resistance.European journal of microbiology & immunology · 2025Article
- Monosaccharides drive Salmonella gut colonization in a context-dependent or -independent manner.Nature communications · 2025Article
- Quantification ofeLife · 2025Article
- Quantification ofbioRxiv : the preprint server for biology · 2024Article
- Commensal E. coli limits Salmonella gut invasion during inflammation by producing toxin-bound siderophores in a tonB-dependent manner.PLoS biology · 2024Article
- The role of tissue resident memory CD4 T cells in Salmonella infection: Implications for future vaccines.Vaccine · 2023Review
- The microbiota conditions a gut milieu that selects for wild-type Salmonella Typhimurium virulence.PLoS biology · 2023Article
- FromACS omega · 2023Review
- Murine Models of Salmonella Infection.Current protocols · 2023Article
- In situ, in vivo, and in vitro approaches for studying AMR plasmid conjugation in the gut microbiome.FEMS microbiology reviews · 2023Review
- The Mobilizable Plasmid P3 of Salmonella enterica Serovar Typhimurium SL1344 Depends on the P2 Plasmid for Conjugative Transfer into a Broad Range of BacteriaJournal of bacteriology · 2022Article
- The Combination of Phages and Faecal Microbiota Transplantation Can Effectively Treat Mouse Colitis Caused byFrontiers in microbiology · 2022Article
- Mechanisms for the Invasion and Dissemination ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Review
- Article
- Regulatory T cells control the dynamic and site-specific polarization of total CD4 T cells following Salmonella infection.Mucosal immunology · 2020Article
- Germ-free and microbiota-associated mice yield small intestinal epithelial organoids with equivalent and robust transcriptome/proteome expression phenotypes.Cellular microbiology · 2020Article
- Gut-resident CX3CR1Science immunology · 2020Article
- Pten gene deletion in intestinal epithelial cells enhances susceptibility to Salmonella Typhimurium infection in mice.Journal of microbiology (Seoul, Korea) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salmonella enterica subspecies 1 serovar Typhimurium is an enteric bacterial pathogen infecting a broad range of hosts. In susceptible Nramp1(-/-) (Slc11alpha1(-/-)) mice, serovar Typhimurium cannot efficiently colonize the intestine but causes a systemic typhoid-like infection. However, after pretreatment with streptomycin, these susceptible (C57BL/6 and BALB/c) mice develop acute serovar Typhimurium-induced colitis (M. Barthel et al., Infect. Immun. 71:2839-2858, 2003). It was not clear whether resistant Nramp1(+/+) (Slc11alpha1(+/+)) mouse strains would similarly develop colitis. Here we compared serovar Typhimurium infection in streptomycin-pretreated susceptible (C57BL/6) and resistant (DBA/2 and 129Sv/Ev) mouse strains: We found that acute colitis (days 1 and 3 postinfection) is strikingly similar in susceptible and resistant mice. In 129Sv/Ev mice we followed the serovar Typhimurium infection for as long as 6 weeks. After the initial phase of acute colitis, these animals developed chronic crypt-destructive colitis, including ulceration, crypt abscesses, pronounced mucosal and submucosal infiltrates, overshooting regeneration of the epithelium, and crypt branching. Moreover, we observed inflammation of the gall duct epithelium (cholangitis) in the 129Sv/Ev mice between days 14 and 43 of infection. Cholangitis was not attributable to side effects of the streptomycin treatment. Furthermore, chronic infection of 129Sv/Ev mice in a typhoid fever model did not lead to cholangitis. We propose that streptomycin-pretreated 129Sv/Ev mice provide a robust murine model for chronic enteric salmonellosis including complications such as cholangitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.